While normal cells repair DSBs through HRR, cancer cells are unable to do so.[8, 9] As a result, PARP‐1 inhibitors block the repair of single‐strand breaks (SSBs), causing these breaks to evolve into DSBs during DNA replication, leading to the death of tumor cells while sparing normal cells. The gene discussed is PARP1; the disease is cancer.